Federated Hermes Inc. Has $1.20 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Key Points

• Federated Hermes Inc. increased its stake in Zentalis Pharmaceuticals by 52.3% in Q1, owning over 752,000 shares valued at approximately $1.2 million.
• Zentalis stock has a current market cap of $99.29 million and a one-year range, with a low of $1.01 and a high of $5.44.
• Analysts maintain a "Moderate Buy" rating on Zentalis, with a price target averaging $8.37, and recent earnings beat consensus estimates by $0.19.

Federated Hermes Inc. grew its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 52.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 752,517 shares of the company's stock after purchasing an additional 258,535 shares during the period. Federated Hermes Inc. owned approximately 1.05% of Zentalis Pharmaceuticals worth $1,197,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in ZNTL. Integral Health Asset Management LLC bought a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at about $3,182,000. Almitas Capital LLC boosted its position in shares of Zentalis Pharmaceuticals by 69.3% during the 4th quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock valued at $4,929,000 after purchasing an additional 665,968 shares in the last quarter. Peapod Lane Capital LLC bought a new position in shares of Zentalis Pharmaceuticals during the 1st quarter valued at about $888,000. Boxer Capital Management LLC bought a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at about $1,364,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Zentalis Pharmaceuticals by 75.7% during the 4th quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock valued at $2,605,000 after purchasing an additional 370,511 shares in the last quarter.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ ZNTL traded down $0.01 during mid-day trading on Friday, reaching $1.44. The company had a trading volume of 497,237 shares, compared to its average volume of 576,408. The stock has a fifty day moving average of $1.37 and a two-hundred day moving average of $1.56. The company has a market capitalization of $103.61 million, a price-to-earnings ratio of -0.64 and a beta of 1.71. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.01 and a 12-month high of $5.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.19. Sell-side analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday. Wedbush reiterated a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. HC Wainwright raised shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a research report on Thursday. Finally, Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a research report on Thursday. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $8.20.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.